{"id":391732,"date":"2014-01-30T00:00:00","date_gmt":"2014-01-30T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dbaspd3514-biopharma-painful-diabetic-neuropathy-decision-base-us-2014\/"},"modified":"2026-04-17T11:45:55","modified_gmt":"2026-04-17T11:45:55","slug":"dbaspd3514-biopharma-painful-diabetic-neuropathy-decision-base-us-2014","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dbaspd3514-biopharma-painful-diabetic-neuropathy-decision-base-us-2014\/","title":{"rendered":"Painful Diabetic Neuropathy | Decision Base | US | 2014"},"content":{"rendered":"<p><em>In an Increasingly Generic Market, Replete with Well-Established Oral Therapies, What Drug Development Opportunities Remain?<\/em><\/p>\n<p>In 2012, painful diabetic neuropathy (PDN) affected more than 7.4 million people in the major pharmaceutical markets under study (United States, France, Germany, Italy, Spain, United Kingdom, and Japan); due to an aging population and increases in obesity and type 2 diabetes, this market is expected to grow to more than 9.5 million by 2022. In addition to offering a rather large treatable patient population, PDN has and will continue to serve as a gateway indication into the broader, more-lucrative neuropathic pain (NP) market. No available therapies for PDN, and NP in general, can fully alleviate patients\u2019 pain; interviewed experts report that, despite the availability of a large array of therapies from multiple drug classes, physicians are at best able to achieve 50% pain relief in 50% of their PDN patients with any single therapy. The limited efficacy and tolerability of currently available therapies translate into a high level of unmet need and potential opportunity for novel agents. However, emerging pain therapies will enter a market that contains many well-established, relatively inexpensive early-line therapies and will encounter a growing generics presence. As a result, emerging therapies attempting to attain premium pricing in this market will need to offer substantial improvements in efficacy, safety, and\/or delivery over currently available therapies to achieve commercial success.<\/p>\n","protected":false},"template":"","class_list":["post-391732","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-diabetic-neuropathy","biopharma-therapy-areas-painful-diabetic-neuropathy","biopharma-geography-us","biopharma-date-574"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/391732","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/391732\/revisions"}],"predecessor-version":[{"id":394855,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/391732\/revisions\/394855"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=391732"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}